Skip to main content
Full access
New Research
Published Online: 1 August 2012

Regional fMRI Hypoactivation and Altered Functional Connectivity During Emotion Processing in Nonmedicated Depressed Patients With Bipolar II Disorder

Abstract

Objective:

Although the amygdala and ventrolateral prefrontal cortex have been implicated in the pathophysiology of bipolar I disorder, the neural mechanisms underlying bipolar II disorder remain unknown. The authors examined neural activity in response to negative emotional faces during an emotion perception task that reliably activates emotion regulatory regions.

Method:

Twenty-one nonmedicated depressed bipolar II patients and 21 healthy comparison subjects underwent functional MRI (fMRI) while performing an emotional face-matching task. Within- and between-group whole-brain fMRI activation and seed-based connectivity analyses were conducted.

Results:

In depressed bipolar II patients, random-effects between-group fMRI analyses revealed a significant reduction in activation in several regions, including the left and right ventrolateral prefrontal cortices (Brodmann's area [BA] 47) and the right amygdala, a priori regions of interest. Additionally, bipolar patients exhibited significantly reduced negative functional connectivity between the right amygdala and the right orbitofrontal cortex (BA 10) as well as the right dorsolateral prefrontal cortex (BA 46) relative to healthy comparison subjects.

Conclusions:

These findings suggest that bipolar II depression is characterized by reduced regional orbitofrontal and limbic activation and altered connectivity in a fronto-temporal circuit implicated in working memory and emotional learning. While the amygdala hypoactivation observed in bipolar II depression is opposite to the direction seen in bipolar I mania and may therefore be state dependent, the observed orbitofrontal cortex hypoactivation is consistent with findings in bipolar I depression, mania, and euthymia, suggesting a physiologic trait marker of the disorder.

Formats available

You can view the full content in the following formats:

Supplementary Material

File (appi.ajp.2012.11030349.ds001.pdf)
Supplementary text

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 831 - 840
PubMed: 22773540

History

Received: 2 March 2011
Revision received: 12 September 2011
Revision received: 19 February 2012
Accepted: 16 March 2012
Published online: 1 August 2012
Published in print: August 2012

Authors

Affiliations

Nathalie Vizueta, Ph.D.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Jeffrey D. Rudie, Ph.D.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Jennifer D. Townsend, B.A.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Salvatore Torrisi, M.A.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Teena D. Moody, Ph.D.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Susan Y. Bookheimer, Ph.D.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.
Lori L. Altshuler, M.D.
From the Semel Institute for Neuroscience and Human Behavior, the Department of Psychiatry and Biobehavioral Sciences, and the Ahmanson-Lovelace Brain Mapping Center and Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California, Los Angeles; and the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles.

Notes

Address correspondence to Dr. Vizueta ([email protected]).

Funding Information

Dr. Altshuler has served on the advisory boards or speakers bureaus of Forest Laboratories, Merck, and Sepracor and has served as a consultant to Eli Lilly. All other authors report no financial relationships with commercial interests.Supported by NIMH grants (K24 MH-01848, T32 MH-17140) and a fellowship from the University of California, Los Angeles, Integrative Study Center in Mood Disorders to Dr. Vizueta; by grants from the National Center for Research Resources (RR12169, RR13642, and RR00865); and by the Ahmanson Foundation, the Brain Mapping Medical Research Organization, the Brain Mapping Support Foundation, the Capital Group Companies Charitable Foundation, the Jennifer Jones-Simon Foundation, the Northstar Fund, the Pierson-Lovelace Foundation, the Robson Family, the Tamkin Foundation, and the William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share